Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.

Subedi L, Bamjan AD, Kim E, Phuyal S, Sapkota B, Kim KT, Cho SS, Shim JH, Seo JB, Park JW

DOI: 10.1016/j.jconrel.2026.115297
Published: 2026 Aug 28
Container: Journal of controlled release : official journal of the Controlled Release Society
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jconrel.2026.115297,
  title = {Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.},
  author = {Subedi L and Bamjan AD and Kim E and Phuyal S and Sapkota B and Kim KT and Cho SS and Shim JH and Seo JB and Park JW},
  year = {2026},
  journal = {Journal of controlled release : official journal of the Controlled Release Society},
  doi = {10.1016/j.jconrel.2026.115297},
  url = {https://doi.org/10.1016/j.jconrel.2026.115297}
}

RIS

TY  - JOUR
TI  - Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.
AU  - Subedi L
AU  - Bamjan AD
AU  - Kim E
AU  - Phuyal S
AU  - Sapkota B
AU  - Kim KT
AU  - Cho SS
AU  - Shim JH
AU  - Seo JB
AU  - Park JW
PY  - 2026
JO  - Journal of controlled release : official journal of the Controlled Release Society
DO  - 10.1016/j.jconrel.2026.115297
UR  - https://doi.org/10.1016/j.jconrel.2026.115297
ER  -

APA

L, S., AD, B., E, K., S, P., B, S., KT, K., SS, C., JH, S., JB, S., & JW, P. (2026). Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.. Journal of controlled release : official journal of the Controlled Release Society. https://doi.org/10.1016/j.jconrel.2026.115297

Source records

pubmed · retrieved 2026-09-26T04:15:59.830Z